Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer

BACKGROUND. Effective new agents for patients with colorectal cancer (CRC) with disease progression during standard therapy regimens are needed. We hypothesized that poly ADP ribose polymerase (PARP) inhibitor therapy in patients with CRC and inefficient tumor DNA repair mechanisms, such as those wi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Leichman, Lawrence, Groshen, Susan, O’Neil, Bert H., Messersmith, Wells, Berlin, Jordan, Chan, Emily, Leichman, Cynthia G., Cohen, Steven J., Cohen, Deirdre, Lenz, Heinz-Josef, Gold, Philip, Boman, Bruce, Fielding, Anitra, Locker, Gershon, Cason, Ronald C., Hamilton, Stan R., Hochster, Howard S.
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2016
Matèries:
Gastrointestinal Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4746089/
https://ncbi.nlm.nih.gov/pubmed/26786262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0319
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars